Skip to main content

Positive interim results for Ra Pharmaceuticals

Ra Pharmaceuticals Inc. (Nasdaq: RARX) reported positive interim results from an ongoing Phase 2 clinical program evaluating RA101495 SC to treat paroxysmal nocturnal hemoglobinuria but the stock price plunged $5.31 to close at $8.92.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.